AI & BIG DATA
Shaping today's innovations
Save up to 25% on AI & Big Data books, eBooks & Journals

Nanotechnology-based therapeutics, operating at scales of billionths of a metre, have great potential for future expansion in altering the scale and methods of drug delivery. The… Read more
AI & BIG DATA
Save up to 25% on AI & Big Data books, eBooks & Journals
List of figures
List of tables
Foreword
Chapter 1: Nanoparticulate systems as drug carriers: the need
Abstract:
1.1 Introduction: nanoparticles for drug delivery
1.2 Need: solubility, bioavailability, targeting and more
1.3 Specific nanoparticulate strategies for overcoming solubility and bioavailability limitations
Chapter 2: Nanoparticles as drug carriers
Abstract:
2.1 Nanoparticles as drug carriers: the scope
2.2 Nanoparticles as drug delivery carriers
2.3 Application areas for nanoparticulate drug delivery systems
2.4 Routes of administration of nanoparticulate drug delivery systems
2.5 Conclusion
Chapter 3: Characterization techniques for nanoparticulate carriers
Abstract:
3.1 Need and challenges for characterization techniques of nanoparticulate drug carriers
3.2 Measuring the size of nanoparticles
3.3 Zeta potential measurement [1, 4]
3.4 Characterizing the morphology of the nanoparticles
3.5 Assessing the sterility and detecting mycoplasma or microbial contamination of nanoparticles [46, 47]
3.6 Toxicity evaluation of nanoparticles
3.7 Evaluating immunological potential of nanoparticles
Chapter 4: Nanotoxicology: evaluating toxicity potential of drug-nanoparticles
Abstract:
4.1 Nanotoxicology: need towards developing safe and sustainable drug delivery systems
4.2 In vitro assays for assessing toxicity of nanoparticles
4.3 In-vivo assays for assessing toxicity of nanoparticles
4.4 Genotoxicity evaluation
Chapter 5: Regulatory aspects of nanoparticulate drug delivery systems
Abstract:
5.1 Nanoparticulate drug carriers: the regulatory facet
5.2 Issues associated with regulating nano-drug delivery systems
5.3 Current approaches for regulating pharmaceutical nanocarriers
Chapter 6: Clinical trials industrial aspects
Abstract:
6.1 Clinical trials of nanoparticulate drug delivery systems: successes and failures
6.2 Case studies: cancer
6.3 Case studies: other diseases
6.4 Nanoparticulate drug delivery: an industrial outlook
Chapter 7: Case studies: nano-systems in the market
Abstract:
7.1 Case studies: performance and market approval
7.2 Are nano or conventional drug delivery systems a better choice? – a market overview
7.3 Future perspectives on nanoparticulate drug carriers
Index
VP
PD
RJ